Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HMGCR | P04035 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11514919 | 0.85 | CA12 (0.50) | CA12CA1CA2CA9TSHR | |
| SCHEMBL11514054 | 0.84 | CA12 (0.48) | CA12CA1CA2CA9TSHR | |
| SCHEMBL10478986 | 0.82 | CA12 (0.37) | CA12CA1CA2CA9TSHR | |
| SCHEMBL27546804 | 0.81 | CA1 (0.47) | CA12CA1CA2CA9TSHR | |
| SCHEMBL9205631 | 0.80 | CA12 (0.45) | CA12CA1CA2CA9TSHR | |
| SCHEMBL2987740 | 0.80 | ALDH1A1 (0.39) | CA12CA1CA2CA9TSHR | |
| SCHEMBL2984011 | 0.80 | CA12 (0.45) | CA12CA1CA2CA9TSHR | |
| SCHEMBL11682030 | 0.80 | CA12 (0.45) | CA12CA1CA2CA9TSHR | |
| SCHEMBL1107421 | 0.80 | CA12 (0.45) | CA12CA1CA2CA9TSHR | |
| SCHEMBL22836427 | 0.78 | CA12 (0.44) | CA12CA1CA2CA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962192-B2 | Nonaqueous electrolytic solution and nonaqueous electrolyte battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-02-24 | — | — | US | disclosed |
| US-8574757-B2 | Nonaqueous electrolytic solution and nonaqueous electrolyte battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2013-11-05 | — | — | US | disclosed |
| CN-102780038-A | Nonaqueous electrolyte battery | MITSUBISHI CHEM CORP | 2012-11-14 | — | — | CN | disclosed |
| US-20120264011-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20100197687-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2010-08-05 | — | — | US | disclosed |
| US-7691898-B2 | Phosphonic acid derivatives and the treating agents of diseases related hyperphosphatemia | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20100035147-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-02-11 | — | — | US | disclosed |
| CN-101622751-A | Nonaqueous electrolyte solution and nonaqueous electrolyte battery | MITSUBISHI CHEM CORP | 2010-01-06 | — | — | CN | disclosed |
| EP-1419182-B1 | IRON-BASED CATALYST COMPOSITION FOR THE MANUFACTURE OF SYNDIOTACTIC 1,2-POLYBUTADIENE | BRIDGESTONE CORP (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-20080119441-A1 | Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| WO-2006077367-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMATION | BIOLIPOX AB (SE) | 2006-07-27 | — | — | WO | disclosed |
| CN-1527844-A | Iron-based catalyst composition for the manufacture of syndiotactic 1.2-polybutadiene | ������������ʽ���� | 2004-09-08 | — | — | CN | disclosed |
| EP-1419182-A1 | IRON-BASED CATALYST COMPOSITION FOR THE MANUFACTURE OF SYNDIOTACTIC 1,2-POLYBUTADIENE | Bridgestone Corporation (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-6610804-B2 | An iron compound, an alpha-acylphosphonate diester, and an organoaluminum compound | BRIDGESTONE CORPORATION (JP) | 2003-08-26 | — | — | US | disclosed |
| US-6576725-B1 | Iron compound, organomagnesium compound, and alpha-acylphosphonate diester; addition polymerization | BRIDGESTONE CORPORATION (JP) | 2003-06-10 | — | — | US | disclosed |
| US-20030073790-A1 | Iron-based catalyst composition for the manufacture of syndiotactic 1, 2-polybutadiene | BRIDGESTONE CORP. | 2003-04-17 | — | — | US | disclosed |
| US-20030073570-A1 | Method of preparing oligomers of conjugated dienes with an iron-based catalyst composition | BRIDGESTONE CORP. | 2003-04-17 | — | — | US | disclosed |
| WO-2003018644-A1 | IRON-BASED CATALYST COMPOSITION FOR THE MANUFACTURE OF SYNDIOTACTIC 1,2-POLYBUTADIENE | BRIDGESTONE CORPORATION (JP) | 2003-03-06 | — | — | WO | disclosed |
| US-4164394-A | USING AN ACYLPHOSPHONATE AS ACTIVATOR | FMC CORPORATION (US) | 1979-08-14 | — | — | US | disclosed |
| US-3998915-A | PROCESS FOR THE PRODUCTION OF 1-ACYLOXY ALKYLENE PHOSPHONIC ACID DIALKYL ESTERS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197687-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, TPH1 | CA12 4385/4885CA1 4132/4885CA2 3546/4885 |
| US-20080119441-A1 | Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia | NR0B1, NR0B2, PTH1R | CA12 797/4885CA1 747/4885CA2 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.